Chrysin, a herbal bioactive molecule, exerts a plethora of pharmacological effects, including anti-oxidant, anti-inflammatory, neuroprotective, and anti-cancer. A growing body of evidence has highlighted the emerging role of chrysin in a variety of neurological disorders, including Alzheimer’s and Parkinson’s disease, epilepsy, multiple sclerosis, ischemic stroke, traumatic brain injury, and brain tumors. Based on the results of recent pre-clinical studies and evidence from studies in humans, this review is focused on the molecular mechanisms underlying the neuroprotective effects of chrysin in different neurological diseases. In addition, the potential challenges, and opportunities of chrysin’s inclusion in the neurotherapeutics repertoire are critically discussed.

The incidence of diabetes has increased globally in recent years and figures of diabetic patients were estimated to rise up to 642 million by 2040. The disorder is accompanied with various complications if not managed at the early stages, and interlinked high mortality rate and morbidity with time. Different classes of drugs are available for the management of type 2 diabetes but were having certain limitations of their safety. Alphaglucosidase is a family of enzyme originated from the pancreas which plays a role in the anabolism of 80-90% of carbohydrate consumed into glucose. This glucose is absorbed into the blood and results in frank postprandial hyperglycemia and worsens the conditions of diabetic patients which precipitate complications. Inhibition of these enzymes helps to prevent postprandial hyperglycemia and the formation of glycated end products. Alphaglucosidase inhibitors are reported to be more important in adequate control of type 2, but marketed drugs have various side effects, such as poor patient compliance and also expensive. This proves the needs for other class of drugs with better efficacy, safety, patient compliance and economic. In this review, we have emphasized the recent advances in the field of new alpha-glucosidase inhibitors with improved safety and pharmacological profile.

The present study was designed to evaluate the antioxidant potential of three natural origin drugs, namely crocin, kaempferol and podophyllotoxin by chemical, biochemical and electrochemical assays. The chemical assay was carried out by DPPH and reducing power assays while the biochemical assay evaluated the lipid peroxidation inhibition capacity, using brain cells as models; the electrochemical characterization was performed by cyclic voltammetry and differential pulse voltammetry using multi-walled carbon nanotube paste electrode (MWCNTPE) in 0.02M acetate buffer (pH 4.5). The superoxide radical scavenging activity was performed at dropping mercury electrode (DME) in 0.1M KCl. All the species proved to have antioxidant activity, and particularly, by the electrochemical techniques, it has been shown that these drugs showed scavenging ability on superoxide anion produced by electrochemical reduction of oxygen. The highest scavenging property of crocin may be due to the hydroxyl and glucose moieties that could provide the necessary component as a radical scavenger